ATOS - Atossa Genetics Inc logo

ATOS

Atossa Genetics Inc

Atossa Therapeutics develops therapies for breast cancer, focusing on its lead candidate, (Z)-endoxifen, a selective estrogen receptor modulator. The company targets high-risk women and aims to reduce breast cancer incidence through innovative treatments.

โš•๏ธ Healthcare NASDAQ Listed 2012 $ USD
$1,000 invested 10 years ago โ†’$3today

Score Overview

1 Year
Scoreโ€”
Net Growth-36.33%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-95.03%
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth-120.62%
Net Trend20%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-4x
Net Trend15%
Net Income Consistency
Rev Growth-100.00%
Rev Trend8%
Revenue Consistency

See the full market ranking โ†’

Atossa Genetics Inc fundamental performance

Between 2015 and 2025, revenue declined from $ 1.76K to $ 0.00 and net income went from -$ 15M to -$ 34M. Revenue increased in 0 of those 10 years; net income in 2.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.35โ€”
1 Year2025-08-12
$ 11.59-79.73%
5 Years2021-08-12
$ 49.65-95.27%
10 Years2016-08-12
$ 675.00-99.65%
All Time2012-11-08
$ 12.96K-99.98%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 34M$ 41M
2024$ 0.00-$ 25M$ 71M
2023$ 0.00-$ 30M$ 88M
2022$ 0.00-$ 26M$ 110M
2021$ 0.00-$ 20M$ 136M
2020$ 0.00-$ 17M$ 39M
2019$ 0.00-$ 17M$ 12M
2018$ 0.00-$ 11M$ 10M
2017$ 0.00-$ 8M$ 7M
2016$ 0.00-$ 6M$ 3M
2015$ 1.76K-$ 15M$ 3M
2014$ 40.14K-$ 14M$ 8M
2013$ 632.56K-$ 10M$ 6M
IPO2012$ 481.84K-$ 5M$ 1M

Explore beyond ATOS

You're looking at Atossa Genetics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies